A Phase 1 Dose Escalation Study of Combination Therapy With Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase 1 Dose Escalation Study of Combination Therapy With Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Pilaralisib (Primary) ; Pimasertib (Primary)
  • Indications Breast cancer; Colorectal cancer; Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Aug 2012 Actual end date (July 2012) added as reported by ClinicalTrials.gov.
    • 26 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top